All Stories

  1. Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?
  2. Hypertension and progressive supranuclear palsy
  3. Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability
  4. End of life planning in parkinsonian diseases
  5. The virtual reality of Parkinson's disease freezing of gait: A systematic review
  6. Progress in the treatment of Parkinson-Plus syndromes
  7. Fall Prediction and Prevention Systems: Recent Trends, Challenges, and Future Research Directions
  8. Therapeutic options for Progressive Supranuclear Palsy including investigational drugs
  9. The Role of Stress as a Risk Factor for Progressive Supranuclear Palsy
  10. Which ante mortem clinical features predict progressive supranuclear palsy pathology?
  11. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?
  12. Psychometric Properties and Characteristics of the North-East Visual Hallucinations Interview in Parkinson's Disease
  13. Neuropsychiatric Predictors of Cognitive Decline in Parkinson Disease: A Longitudinal Study
  14. Understanding falls in progressive supranuclear palsy
  15. Progression of brain atrophy in PSP and CBS over 6 months and 1 year
  16. Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale
  17. Abolishing the 1-year rule: How much evidence will be enough?
  18. Environmental Exposures and Parkinson’s Disease
  19. Cognitive functioning in individuals with Parkinson’s disease and traumatic brain injury: A longitudinal study
  20. Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy
  21. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials
  22. Progression of Microstructural Degeneration in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Longitudinal Diffusion Tensor Imaging Study
  23. Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease
  24. α-synuclein genetic variability: A biomarker for dementia in Parkinson disease
  25. The new definition and diagnostic criteria of Parkinson's disease
  26. Technology in Parkinson's disease: Challenges and opportunities
  27. Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy
  28. Relationship between uric acid levels and progressive supranuclear palsy
  29. Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study
  30. Neuropsychiatric symptoms and their impact on quality of life in multiple system atrophy
  31. Progressive supranuclear palsy: progression and survival
  32. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy
  33. Structural MRI Correlates of Episodic Memory Processes in Parkinson’s Disease Without Mild Cognitive Impairment
  34. Swallowing disturbances in the corticobasal syndrome
  35. Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis
  36. Head injury exposure in PSP: a case-control study
  37. MDS clinical diagnostic criteria for Parkinson's disease
  38. MDS research criteria for prodromal Parkinson's disease
  39. The RAB39B p.G192R mutation causes X-linked dominant Parkinson’s disease
  40. Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers)
  41. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy
  42. Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report
  43. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
  44. NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases
  45. Pathophysiology, genetics, clinical features, diagnosis and therapeutic trials in progressive supranuclear palsy
  46. The Wearable Multimodal Monitoring System: A Platform to Study Falls and Near-Falls in the Real-World
  47. Correcting for Demographic Variables on the Modified Telephone Interview for Cognitive Status
  48. A disposable electrochemical biosensor for l-DOPA determination in undiluted human serum
  49. Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (STACCATO)
  50. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease
  51. Faculty Opinions recommendation of Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study.
  52. P3‐165: MILD COGNITIVE IMPAIRMENT AMONG PARKINSON'S DISEASE SUBJECTS IN THE UNIFORM DATA SET
  53. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial
  54. Corticobasal Degeneration
  55. The utility of the Mattis Dementia Rating Scale in Parkinson's disease mild cognitive impairment
  56. Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status
  57. A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
  58. Cognition in movement disorders: Where can we hope to be in ten years?
  59. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease
  60. Instrumental activities of daily living are impaired in Parkinson’s disease patients with mild cognitive impairment.
  61. Rate of decline in progressive supranuclear palsy
  62. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy
  63. Dissociation of Neural Mechanisms for Intersensory Timing Deficits in Parkinson’s Disease
  64. Pan-American Consortium of Multiple System Atrophy (PANMSA). A Pan-American multicentre cohort study of Multiple System Atrophy
  65. Parkinson's Disease Mild Cognitive Impairment: Application and Validation of the Criteria
  66. Behavioral abnormalities in progressive supranuclear palsy
  67. Faculty Opinions recommendation of Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.
  68. Primary Health Care Providers' Knowledge Gaps on Parkinson's Disease
  69. Predictors of performance-based measures of instrumental activities of daily living in nondemented patients with Parkinson’s disease
  70. Parkinsonian Syndromes
  71. Volumetric correlates of cognitive functioning in nondemented patients with Parkinson's disease
  72. Neuropsychiatric and cognitive disorders in other parkinsonian disorders
  73. Faculty Opinions recommendation of The natural history of multiple system atrophy: a prospective European cohort study.
  74. P4–096: APOE‐ɛ4 and clinical progression in Parkinson's disease
  75. The meaning of a “hippo” response on the Montreal Cognitive Assessment in Parkinson's disease
  76. Measuring mild cognitive impairment in patients with Parkinson's disease
  77. Criteria for the diagnosis of corticobasal degeneration
  78. Functional impairment in progressive supranuclear palsy
  79. White-Matter Changes Correlate with Cognitive Functioning in Parkinson’s Disease
  80. Long-duration Parkinson's disease: Role of lateralization of motor features
  81. Impact of Mild Cognitive Impairment on Health-Related Quality of Life in Parkinson's Disease
  82. The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer’s disease
  83. Toward magnetic resonance imaging biomarkers for progressive supranuclear palsy and multisystem atrophy
  84. Faculty Opinions recommendation of Pareidolias: complex visual illusions in dementia with Lewy bodies.
  85. Faculty Opinions recommendation of Parkinson subtypes progress differently in clinical course and imaging pattern.
  86. Executive Dysfunction Is the Primary Cognitive Impairment in Progressive Supranuclear Palsy
  87. Reply: Mild cognitive impairment in de novo Parkinson's disease according to Movement Disorder guidelines
  88. The pill questionnaire in a nondemented Parkinson's disease population
  89. Faculty Opinions recommendation of Clinical features of Parkinson disease when onset of diabetes came first: A case-control study.
  90. Pan-American Consortium of Multiple System Atrophy. Preliminary Report (P06.079)
  91. Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study
  92. Meta-analysis of Parkinson's Disease: Identification of a novel locus, RIT2
  93. Phosphorylated  -Synuclein in Parkinson's Disease
  94. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines
  95. Annonacin in Asimina triloba fruit: Implication for neurotoxicity
  96. Roles of Education and IQ in Cognitive Reserve in Parkinson’s Disease-Mild Cognitive Impairment
  97. Faculty Opinions recommendation of Quantitative EEG as a predictive biomarker for Parkinson disease dementia.
  98. Cytokine expression and microglial activation in progressive supranuclear palsy
  99. Faculty Opinions recommendation of α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies.
  100. Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome
  101. Parkinsonism and Frontotemporal Dementia: The Clinical Overlap
  102. Progressive Supranuclear Palsy and Corticobasal Degeneration
  103. Brain-Lung-Thyroid Disease
  104. Copy Number Variation in Familial Parkinson Disease
  105. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy
  106. MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI
  107. Faculty Opinions recommendation of Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.
  108. Milestones in atypical and secondary Parkinsonisms
  109. Assessment of cognition in early dementia
  110. Woman with gait impairment and difficulty reading
  111. Faculty Opinions recommendation of Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
  112. A recommended scale for cognitive screening in clinical trials of Parkinson's disease
  113. Cognitive and neuropsychiatric effects of subthalamotomy for Parkinson’s disease
  114. Faculty Opinions recommendation of Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease.
  115. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease
  116. Rapidly progressive atypical parkinsonism associated with frontotemporal lobar degeneration and motor neuron disease
  117. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy
  118. Faculty Opinions recommendation of Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.
  119. H1/H1 genotype influences symptom severity in corticobasal syndrome
  120. Faculty Opinions recommendation of Increased melanoma risk in Parkinson disease: a prospective clinicopathological study.
  121. Bradykinesia
  122. Tauopathies
  123. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms
  124. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria
  125. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort
  126. Genomewide association study for onset age in Parkinson disease
  127. Faculty Opinions recommendation of Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration.
  128. Faculty Opinions recommendation of Cerebellar involvement in progressive supranuclear palsy: A clinicopathological study.
  129. Faculty Opinions recommendation of A controlled trial of antidepressants in patients with Parkinson disease and depression.
  130. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options
  131. Review article Progressive supranuclear palsy revisited
  132. Reply: Corticobasal syndrome with Alzheimer's disease pathology
  133. Parkinson’s Disease: An Overview of Pathogenesis
  134. Is it PD, PSP, CBD, DLB, or MSA?
  135. Faculty Opinions recommendation of Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy.
  136. Genomewide association study for susceptibility genes contributing to familial Parkinson disease
  137. The Gly2019Ser mutation in LRRK2is not fully penetrant in familial Parkinson's disease: the GenePD study
  138. Faculty Opinions recommendation of Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity.
  139. Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: The GenePD study
  140. Replication of association between ELAVL4 and Parkinson disease: the GenePD study
  141. Haplotypes and gene expression implicate the MAPT region for Parkinson disease: The GenePD Study
  142. Faculty Opinions recommendation of Vestibular, saccadic and fixation abnormalities in genetically confirmed Friedreich ataxia.
  143. Progressive supranuclear palsy and corticobasal degeneration: similarities and differences
  144. Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)
  145. Preface
  146. Current and future therapeutic approaches in progressive supranuclear palsy
  147. Biology and Neuropathology of Dementia in Syphilis and Lyme Disease
  148. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
  149. Clinical and Therapeutic Aspects of Dementia in Syphilis and Lyme Disease
  150. Clinical aspects and biology of normal pressure hydrocephalus
  151. Clinical aspects of Parkinson dementia
  152. Clinical symptoms in Alzheimer's disease
  153. History of Dementia
  154. Mild cognitive impairment
  155. Neuropathology and genetics of corticobasal degeneration
  156. Neuropathology of Pick body disease
  157. Neuropathology of Hereditary Forms of Frontotemporal Dementia and Parkinsonism
  158. Perspectives of Alzheimer's disease treatments
  159. Quality of Life in Dementias
  160. The Epidemiology of vascular dementia
  161. The Neuropathology of Vascular and Mixed Dementia and Vascular Cognitive Impairment
  162. Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force
  163. Update of atypical parkinsonian disorders
  164. Clinical diagnostic criteria for dementia associated with Parkinson's disease
  165. The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II
  166. The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I
  167. Identification of a Novel Risk Locus for Progressive Supranuclear Palsy by a Pooled Genomewide Scan of 500,288 Single-Nucleotide Polymorphisms
  168. Faculty Opinions recommendation of Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial.
  169. Faculty Opinions recommendation of Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.
  170. Neurobiology of Progressive Supranuclear Palsy
  171. Unraveling progressive supranuclear palsy: from the bedsideback to the bench
  172. Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: The GenePD Study
  173. Alzheimer's disease presenting as corticobasal syndrome
  174. Measuring quality of life in PSP
  175. Faculty Opinions recommendation of Compulsive drug use linked to sensitized ventral striatal dopamine transmission.
  176. Atypical Parkinsonian Disorders--Clinical and Research Aspects * Edited by Irene Litvan * Human Press, 2005. ISBN 1-588-29-331-9. $175.00
  177. Influence of Heterozygosity for Parkin Mutation on Onset Age in Familial Parkinson Disease
  178. Current and future treatments in progressive supranuclear palsy
  179. Penguins and hummingbirds: Midbrain atrophy in progressive supranuclear palsy
  180. Faculty Opinions recommendation of Substantia nigra tangles are related to gait impairment in older persons.
  181. Faculty Opinions recommendation of A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.
  182. Book Review Drug Induced Movement Disorders Second edition. Edited by Stewart A. Factor, Anthony E. Lang, and William J. Weiner. 466 pp. Malden, Mass., Blackwell Futura, 2005. $120. 1-4051-2619-1
  183. Lrrk2 and Lewy body disease
  184. Midbrain atrophy in progressive supranuclear palsy: comparison of two dimensional planimetric- with three dimensional volumetric measurements
  185. BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study
  186. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
  187. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy
  188. Cognitive and behavioral aspects of PSP since Steele, Richardson and Olszewski’s description of PSP 40 years ago and Albert’s delineation of the subcortical dementia 30 years ago
  189. “Applause sign” helps to discriminate PSP from FTD and PD
  190. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome
  191. Bilateral subthalamotomy in Parkinson's disease: initial and long-term response
  192. Atypical Parkinsonian Disorders
  193. What is an Atypical Parkinsonian Disorder?
  194. Progressive Supranuclear Palsy
  195. Progressive Supranuclear Palsy and Corticobasal Degeneration
  196. Update on progressive supranuclear palsy
  197. ATYPICAL PARKINSONIAN DISORDERS
  198. Diagnostic issues in non-AD dementias
  199. Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration
  200. Verifying Clinical Criteria for Parkinsonian Disorders with CART Decision Trees
  201. Correlation of dopamine transporter imaging with parkinsonian motor handicap: How close is it?
  202. Update on epidemiological aspects of progressive supranuclear palsy
  203. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease
  204. SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
  205. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy
  206. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia
  207. Yes/no reversals as neurobehavioral sequela: a disorder of language, praxis, or inhibitory control?
  208. Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration
  209. Freezing of gait in postmortem‐confirmed atypical parkinsonism
  210. Mitochondrial Dysfunction in Cybrid Lines Expressing Mitochondrial Genes from Patients with Progressive Supranuclear Palsy
  211. Corticobasal Degeneration and Related Disorders
  212. Effects of closed traumatic brain injury and genetic factors on the development of Alzheimer's disease
  213. Neuropsychiatric assessment of Gilles de la Tourette patients: Comparative study with other hyperkinetic and hypokinetic movement disorders
  214. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy
  215. Traumatic brain injury as a risk factor for Alzheimer disease. Comparison of two retrospective autopsy cohorts with evaluation of ApoE genotype
  216. Tau genotype: No effect on onset, symptom severity, or survival in progressive supranuclear palsy
  217. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype
  218. Therapy and management of frontal lobe dementia patients
  219. Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy
  220. An open letter to the Committee on The Nobel Prize in Medicine
  221. Impairment of eyeblink classical conditioning in progressive supranuclear palsy
  222. Progression of Dysarthria and Dysphagia in Postmortem-Confirmed Parkinsonian Disorders
  223. Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson's Disease
  224. Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson's Disease
  225. Diagnosis and Management of Progressive Supranuclear Palsy
  226. The FAB
  227. Progression of Hoehn and Yahr stages in parkinsonian disorders: A clinicopathologic study
  228. Research goals in progressive supranuclear palsy
  229. Scientific position paper of the Movement Disorder Society evaluation of surgery for Parkinson's disease
  230. Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy
  231. Language disturbances in corticobasal degeneration
  232. Pupillary diameter assessment: Need for a graded scale
  233. Frontal Assessment Battery
  234. Importance of deficits in executive functions
  235. Evaluation of surgery for Parkinson’s disease
  236. Progression of falls in postmortem-confirmed Parkinsonian disorders
  237. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study
  238. Atypical parkinsonism in the French West Indies
  239. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias
  240. Recent advances in atypical parkinsonian disorders
  241. Effects of Physostigmine on Swallowing and Oral Motor Functions in Patients with Progressive Supranuclear Palsy: A Pilot Study
  242. Association of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy
  243. Clinicopathologic Case Report
  244. Consensus statement on the diagnosis of multiple system atrophy
  245. Ideomotor apraxia in progressive supranuclear palsy: A case study
  246. Ideomotor apraxia in progressive supranuclear palsy: A case study
  247. A lack of the R406W tau mutation in progressive supranuclear palsy and corticobasal degeneration
  248. Consensus statement on the diagnosis of multiple system atrophy
  249. Parkinsonian Features
  250. Caregiving in progressive supranuclear palsy
  251. Neuropsychiatric features of corticobasal degeneration
  252. Neuropsychiatric Assessment of Patients With Hyperkinetic and Hypokinetic Movement Disorders
  253. Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study
  254. Reliability of the NINDS Myotatic Reflex Scale
  255. Pharmacological Therapy in Progressive Supranuclear Palsy
  256. Is EEG useful in the differential diagnosis of parkinsonism?
  257. Apathy Is Not Depression
  258. Dysfunction of Ib (Autogenic) spinal inhibition in patients with progressive supranuclear palsy
  259. Clinical and Genetic Aspects of Progressive Supranuclear Palsy
  260. Accuracy of the Clinical Diagnoses of Lewy Body Disease, Parkinson Disease, and Dementia With Lewy Bodies
  261. Progressive supranuclear palsy
  262. Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy
  263. Apolipoprotein Eepsilon4 (Epsilon) Allele Does Not Affect the Onset or Symptom Severity in Progressive Supranuclear Palsy
  264. What are the Obstacles for an Accurate Clinical Diagnosis of Pick's disease?
  265. Methodological and Research Issues in the Evaluation of Biological Diagnostic Markers for Alzheimer’s Disease
  266. Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI). 22The ...
  267. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination
  268. PROGRESSIVE SUPRANUCLEAR PALSY
  269. Limb shaking in multiple system atrophy
  270. Progressive supranuclear gaze palsy is in linkage disequilibrium with theτ and not the α-synuclein gene
  271. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration
  272. What Is the Accuracy of the Clinical Diagnosis of Multiple System Atrophy?
  273. The clinical and pathologic hallmarks of progressive supranuclear palsy
  274. Supranuclear gaze palsy and eyelid apraxia in postencephalitic parkinsonism
  275. What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study
  276. Characterizing swallowing abnormalities in progressive supranuclear palsy
  277. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study
  278. Accuracy of the Clinical Diagnosis of Corticobasal Degeneration: A Clinicopathologic Study
  279. REPLY FROM THE AUTHORS
  280. A Reappraisal of Reliability and Validity Studies in Stroke
  281. Neuropsychiatric aspects of progressive supranuclear palsy
  282. Can tropicamide eye drop response differentiate patients with progressive supranuclear palsy and Alzheimer's disease from healthy control subjects?
  283. Reliability of the NINDS Myotatic Reflex Scale
  284. Preserved cognitive processes in cerebellar degeneration
  285. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop
  286. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.
  287. Visualizing Cortical Activation during Mental Calculation with Functional MRI
  288. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)
  289. Progressive supranuclear palsy: a clinicopathological study of 21 cases
  290. 641 Accuracy of the clinical diagnosis of pick's disease
  291. Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related Disorders
  292. What can artificial neural networks teach us about neurodegenerative disorders with extrapyramidal features?
  293. Neuropsychological Features of Progressive Supranuclear Palsy
  294. What can preservation of autobiographic memory after muscarinic blockade tell us about the scopolamine model of dementia?
  295. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy)
  296. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy
  297. Cognitive disturbances in progressive supranuclear palsy
  298. Cholinergic approaches to the treatment of progressive supranuclear palsy
  299. Cerebellar cognition
  300. Cognitive planning deficit in patients with cerebellar atrophy
  301. CSF galanin and neuropeptide Y immunoreactivity in progressive supranuclear palsy
  302. Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.
  303. Progressive supranuclear palsy
  304. Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease.
  305. Effects of Physostigmine on Spatial Attention in Patients With Progressive Supranuclear Palsy
  306. Selective Deficits in Alzheimer and Parkinsonian Dementia: Visuospatial Function
  307. Selective deficits in cognition and memory in high-functioning parkinsonian patients.
  308. Frontal Lobe Function in Progressive Supranuclear Palsy
  309. Implicit Learning in Patients with Alzheimer's Disease
  310. Physostigmine treatment of progressive supranuclear palsy
  311. Memory Impairment in Patients With Progressive Supranuclear Palsy
  312. Multiple Memory Deficits in Patients With Multiple Sclerosis
  313. Slowed Information Processing in Multiple Sclerosis
  314. Unilateral left cerebral deterioration documented by CT, MRI, and neuropsychological studies: A possible case of pick's disease
  315. Behcet's syndrome masquerading as tumor
  316. Does reversed laterality really exist in dextrals? A case study
  317. Agitation and Apathy in Hyper- and Hypokinetic Movement Disorders
  318. Measuring quality of life in progressive supranuclear palsy
  319. Management of cognitive impairment in Parkinson's disease
  320. Faculty of 1000 evaluation for Associations between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease.
  321. Case Studies